Phase III Tekturna Diabetes Data Could Further Differentiate Drug From Competing Hypertension Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Development partner Speedel tells “The Pink Sheet” DAILY that hypertension treatments “need to offer something more than blood pressure lowering.”
You may also be interested in...
Novartis To Pull Valturna From U.S. Market As FDA Warns Of Risks With Aliskiren Meds
FDA warns that use of aliskiren-containing blood pressure drugs with ACE inhibitors or angiotensin receptor blockers may increase risk of kidney impairment, hypotension and hyperkalemia; Novartis to continue to sell four other aliskiren products.
Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Fixed-dose blood pressure pill will reach market in early February, Novartis tells “The Pink Sheet” DAILY.
Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Fixed-dose blood pressure pill will reach market in early February, Novartis tells “The Pink Sheet” DAILY.